Murcia Oscar, Martínez-Roca Alejandro, Juárez Miriam, Giner-Calabuig Mar, Alustiza Miren, Mira Cristina, Mangas-Sanjuan Carolina, Serrano Eva, Ruiz-Gómez Francisco Antonio, Baile-Maxia Sandra, Medina Lucía, Alenda Cristina, Payá Artemio, Rodriguez-Soler María, Zapater Pedro, Jover Rodrigo
Instituto de Investigación Sanitaria ISABIAL, Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, 03010 Alicante, Spain.
Unidad de Investigación, Instituto de Investigación Sanitaria ISABIAL, Hospital General Universitario de Alicante, 03010 Alicante, Spain.
Cancers (Basel). 2021 Jan 11;13(2):246. doi: 10.3390/cancers13020246.
The utility of molecular markers for predicting the risk of metachronous advanced colorectal lesions (MACLs) remains poorly investigated. We examined the relationship between somatic hypermethylation in polyps at baseline and the risk of developing MACL. This retrospective cohort study included 281 consecutive patients with colonic polyps who were enrolled between 2007 and 2009 and followed-up until 2014. MACLs were defined as adenomas of ≥10 mm, high-grade dysplasia, or with a villous component; and serrated lesions of ≥10 mm or with dysplasia. In total, 595 polyps were removed at baseline colonoscopy and analyzed for pathological characteristics and CpG island methylator phenotype (CIMP) using the MS-MLPA (Methylation-Specific -- Multiplex Ligation-dependent Probe Amplification) technique. Forty-five patients (16.0%) showed at least one CIMP+ polyp. MACL risk was higher in patients with CIMP+ polyps (odds ratio (OR), 4.50; 95% CI, 1.78-11.4; = 0.002). Patients with CIMP+ polyps also exhibited shorter time to MACL development (33.8 months vs. 50.1 months; < 0.001), even with adjustment for polyp size and number (OR, 2.40; 95% CI, 1.33-4.34). Adding CIMP analysis improved the sensitivity (57.0% to 70.9%), negative predictive value (71.1% to 77.3%), and overall accuracy (49.8% to 52.0%) for MACL risk estimation. These results highlight that CIMP may be a useful marker for endoscopic surveillance.
用于预测异时性晚期结直肠病变(MACL)风险的分子标志物的效用仍未得到充分研究。我们研究了基线时息肉中的体细胞高甲基化与发生MACL风险之间的关系。这项回顾性队列研究纳入了2007年至2009年间连续入选的281例结肠息肉患者,并随访至2014年。MACL定义为直径≥10 mm的腺瘤、高级别异型增生或具有绒毛成分的腺瘤;以及直径≥10 mm或伴有异型增生的锯齿状病变。在基线结肠镜检查时共切除595个息肉,并使用MS-MLPA(甲基化特异性多重连接依赖探针扩增)技术分析其病理特征和CpG岛甲基化表型(CIMP)。45例患者(16.0%)显示至少有一个CIMP+息肉。CIMP+息肉患者发生MACL的风险更高(优势比(OR)为4.50;95%置信区间为1.78 - 11.4;P = 0.002)。即使在调整息肉大小和数量后,CIMP+息肉患者发生MACL的时间也更短(33.8个月对50.1个月;P < 0.001)(OR为2.40;95%置信区间为1.33 - 4.34)。增加CIMP分析可提高MACL风险评估的敏感性(从57.0%提高到70.9%)、阴性预测值(从71.1%提高到77.3%)和总体准确性(从49.8%提高到52.0%)。这些结果表明,CIMP可能是内镜监测的一个有用标志物。